Publications by authors named "W Dieter Paar"
Article Synopsis
- - The TIM-HF2 study showed that remote patient management (RPM) significantly reduces the number of days lost due to hospital admissions or death in heart failure (HF) patients, particularly those with diabetes, with hazard ratios indicating improved outcomes.
- - In a follow-up analysis including 707 HF patients with diabetes, RPM led to a notable decrease in unplanned cardiovascular hospitalizations and all-cause mortality compared to usual care, along with enhanced quality of life as measured by the Minnesota Living with Heart Failure Questionnaire.
- - Overall, the findings support implementing RPM for heart failure patients with diabetes to improve health outcomes and quality of life, indicating its effectiveness in a specific high-risk population.
Aim: To identify predictive factors for diabetic ketoacidosis (DKA) by retrospective analysis of registry data and the use of a subgroup discovery algorithm.
Materials And Methods: Data from adults and children with type 1 diabetes and more than two diabetes-related visits were analysed from the Diabetes Prospective Follow-up Registry. Q-Finder, a supervised non-parametric proprietary subgroup discovery algorithm, was used to identify subgroups with clinical characteristics associated with increased DKA risk.
Background: Patients who experience an acute coronary syndrome (ACS) are at high risk of further cardiovascular events. Long-term treatment of cardiovascular risk factors, such as hyperlipidemia, is critical to prevent progression of coronary heart disease. However, many patients do not reach recommended target levels for low-density lipoprotein (LDL) cholesterol, despite receiving lipid-lowering therapy.
View Article and Find Full Text PDFBackground: Familial hypercholesterolemia (FH) is a highly prevalent disorder and a risk factor for early coronary artery disease. The objective of this registry was to document the clinical characteristics of patients with definite FH in Germany and to document lipid profiles, lipid-lowering therapy, and lipid target achievement during longitudinal follow-up. Methods: HYDRA-FH was a national, prospective, multicenter, non-interventional registry conducted in 35 centers in Germany.
View Article and Find Full Text PDFBackground: Atherosclerotic cardiovascular disease is the leading cause of death and disability in the Western world.
Objective: To characterise adults with confirmed coronary heart disease (CHD) and primary heterozygous familial or non-familial hypercholesterolaemia or mixed dyslipidaemia who received alirocumab in a real-world setting.
Methods: This open, prospective, multicentre, non-interventional study, conducted in Germany, enroled patients with confirmed CHD who were treated with alirocumab according to its summary of product characteristics.